Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
BNTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$76.53 - $131.49
Previous CloseN/A
Volume316.50K
Average Volume (3M)949.33K
Market Cap
$22.08B
Enterprise Value$10.67B
Total Cash (Recent Filing)-€172.35M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 05, 2025EPS Estimate
-2.25Last Dividend Ex-Date
Jun 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-3.02
Shares Outstanding239,970,810
10 Day Avg. Volume1,040,964
30 Day Avg. Volume949,325
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.62
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$139.56Price Target Upside51.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsBNT327 combined with chemotherapy demonstrated an 87.5% objective response rate and superior median progression-free and overall survival in extensive-stage small cell lung cancer patients compared to benchmark trials.
Company FinancialsBioNTech ended the year with approximately €17.4 billion in cash, cash equivalents, and marketable securities, indicating strong financial health.
Financial PerformanceBioNTech recorded net earnings per diluted share of €1.08, surpassing the previous forecast of €0.04 per share.
Bears Say
Data Maturity ConcernsThere remains a key concern on whether the preliminary signals, especially overall survival, can hold as the data is still highly immature.
Financial OutlookThe projection for a full-year net loss per diluted share increased to €4.87 from the prior estimate of €4.64, raising concerns about future profitability.
---
Ownership Overview
― Insiders
4.58% Mutual Funds
13.91% Other Institutional Investors
80.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BNTX FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was $76.53 and its highest was $131.49 in the past 12 months.
What is BioNTech SE’s market cap?
BioNTech SE’s market cap is $22.08B.
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is May 05, 2025 which is in 30 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Mar 10, 2025. The company reported $1.179 earnings per share for the quarter, beating the consensus estimate of $0.488 by $0.691.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE pays a Notavailable dividend of $1.534 which represents an annual dividend yield of N/A. See more information on BioNTech SE dividends here
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is -2.25.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 239,970,810 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of $1.179 in its last earnings report, beating expectations of $0.488. Following the earnings report the stock price went down -3.153%.
Which hedge fund is a major shareholder of BioNTech SE?
Currently, no hedge funds are holding shares in BNTX
---
BioNTech SE Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$139.56 (51.68% Upside)
$139.56 (51.68% Upside)
Blogger Sentiment
Bullish
BNTX Sentiment 80%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 548.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $137.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.35%
12-Months-Change
Fundamentals
Return on Equity
-3.38%
Trailing 12-Months
Asset Growth
-8.20%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE is a German biotechnology company that specializes in developing and producing immunotherapies for the treatment of cancer and other serious diseases. The company is at the forefront of messenger RNA (mRNA) technology and has been instrumental in the development of vaccines, particularly its notable collaboration with Pfizer to produce a COVID-19 vaccine. BioNTech's core products focus on personalized cancer treatments, infectious disease vaccines, and regenerative medicines.
---
BNTX Company Deck
---
BNTX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a mixed outlook for BioNTech. While there are significant advancements in their oncology pipeline and strategic acquisitions like Biotheus, challenges remain with declining COVID-19 vaccine revenues and ongoing legal costs. Financial losses for 2024 also highlight some operational difficulties. The sentiment is balanced between optimism for future growth and caution due to current financial and operational challenges.Read More>---
BNTX Stock 12 Month Forecast
Average Price Target
$139.56
▲(51.68% Upside)
Technical Analysis
Best Analysts Covering BNTX
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
-9.89%
initiated a buy rating last month
Copying William Maughan's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -9.89% per trade.
---